Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Enterprise Value (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Enterprise Value for 16 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 109.69% to -$8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.6 million through Dec 2025, down 109.69% year-over-year, with the annual reading at -$8.6 million for FY2025, 109.69% down from the prior year.
  • Enterprise Value for Q4 2025 was -$8.6 million at Harvard Bioscience, down from -$6.8 million in the prior quarter.
  • The five-year high for Enterprise Value was -$3.8 million in Q1 2023, with the low at -$8.6 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$5.4 million, with a median of -$5.2 million recorded in 2022.
  • The sharpest move saw Enterprise Value tumbled 137.24% in 2021, then soared 42.36% in 2022.
  • Over 5 years, Enterprise Value stood at -$7.8 million in 2021, then skyrocketed by 42.36% to -$4.5 million in 2022, then grew by 4.99% to -$4.3 million in 2023, then rose by 4.09% to -$4.1 million in 2024, then tumbled by 109.69% to -$8.6 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$8.6 million, -$6.8 million, and -$7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.